Published in Proc Natl Acad Sci U S A on August 20, 1996
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood (2010) 2.48
Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest (2005) 2.01
Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol (1999) 1.80
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.80
Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci U S A (1997) 1.65
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med (1999) 1.61
Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A (1997) 1.47
STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood (2006) 1.46
Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol (2000) 1.44
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res (2013) 1.43
STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle (2013) 1.33
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A (2000) 1.27
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol (2000) 1.27
Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology (2005) 1.23
Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A (1999) 1.22
STAT signaling in the pathogenesis and treatment of cancer. Mol Med (1999) 1.11
Design of conditionally active STATs: insights into STAT activation and gene regulatory function. Mol Cell Biol (1999) 1.11
The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther (2011) 1.10
Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood (2013) 1.09
Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One (2010) 1.07
Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol (2008) 1.05
STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer (2011) 1.05
Interleukin-16 as a marker of Sézary syndrome onset and stage. J Clin Immunol (2010) 0.93
Functionally Distinct Subpopulations of CpG-Activated Memory B Cells. Sci Rep (2012) 0.93
Changing partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections. JAKSTAT (2013) 0.92
Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. Am J Pathol (2001) 0.92
Recent advances in the understanding of interleukin-2 signal transduction. J Clin Immunol (1998) 0.91
T-cell growth transformation by herpesvirus saimiri is independent of STAT3 activation. J Virol (2005) 0.91
Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation. J Virol (1998) 0.90
Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol (1997) 0.88
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol (2016) 0.87
Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther (2012) 0.85
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood (2016) 0.85
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget (2015) 0.84
A novel regulation of VEGF expression by HIF-1α and STAT3 in HDM2 transfected prostate cancer cells. J Cell Mol Med (2012) 0.84
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins. PLoS One (2009) 0.84
The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. Blood Cancer J (2014) 0.84
Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndrome. Oncotarget (2016) 0.83
Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome. J Invest Dermatol (2014) 0.82
Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome. Photodermatol Photoimmunol Photomed (2010) 0.81
Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming. J Immunol (2013) 0.78
EPHA4 is overexpressed but not functionally active in Sézary syndrome. Oncotarget (2015) 0.76
Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer. Mediators Inflamm (2016) 0.75
Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation. Int J Biomed Sci (2011) 0.75
JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. Mol Cell Endocrinol (2017) 0.75
Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490. J Inflamm (Lond) (2009) 0.75
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science (1995) 11.16
Lymphocyte responses and cytokines. Cell (1994) 8.35
Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity (1995) 7.08
Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell (1993) 6.83
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 6.65
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J (1994) 5.69
Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science (1993) 5.22
Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A (1995) 5.06
Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science (1995) 4.85
Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science (1993) 4.63
Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50
Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science (1993) 4.39
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity (1995) 3.99
Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J (1995) 3.59
Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science (1994) 3.46
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science (1995) 3.43
Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature (1994) 3.36
Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature (1994) 3.31
Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol (1992) 3.20
TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol (1985) 3.18
Cytokine signaling through nonreceptor protein tyrosine kinases. Science (1995) 3.16
Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science (1995) 3.15
Defective lymphoid development in mice lacking Jak3. Science (1995) 3.04
Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science (1995) 3.00
The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol (1993) 2.96
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature (1995) 2.93
Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science (1994) 2.65
Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol (1995) 2.61
Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell (1995) 2.52
Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood (1995) 2.19
Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci U S A (1995) 1.89
Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood (1996) 1.85
Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol (1990) 1.67
Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med (1992) 1.61
Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J Clin Pathol (1987) 1.59
Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMBO J (1994) 1.50
Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int Immunol (1995) 1.39
The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunol Rev (1994) 1.30
Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol (1992) 1.23
IL-2 mRNA expression in Tac-positive malignant lymphomas. Am J Pathol (1990) 1.17
Interleukin-2 induces tyrosine phosphorylation and nuclear translocation of stat3 in human T lymphocytes. Eur J Immunol (1994) 1.14
A clonal CD4-positive T-cell line established from the blood of a patient with Sézary syndrome. J Invest Dermatol (1991) 0.95
Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. Am J Pathol (1991) 0.92
Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas. Blood (1994) 0.91
Diagnostic criteria in Sézary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol (1983) 0.89
Differential effects of cytokines on proliferative response of human CD4+ T lymphocyte subsets stimulated via T cell receptor-CD3 complex. J Immunol (1990) 0.84
Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood (1985) 0.80
Preferential interaction of the CD4+29+/45RA-subset of human CD4+ T lymphocytes with an antibody against the cell-membrane ganglioside GD3. Scand J Immunol (1992) 0.78
[Structure and function of IL-2 receptor subunits]. Hum Cell (1994) 0.78
A majority of proliferating T cells in cutaneous malignant T cell lymphomas may lack the high affinity IL-2 receptor (CD25). Arch Dermatol Res (1993) 0.77
The clonal evolution of tumor cell populations. Science (1976) 24.39
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (1984) 8.80
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med (1982) 5.72
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Mixed hematopoietic and pulmonary origin of 'alveolar macrophages' as demonstrated by chromosome markers. Am J Pathol (1966) 4.08
Quantitative studies on the mixed lymphocyte interaction in rats. II. Relationship of the proliferative response to the immunologic status of the donors. J Exp Med (1967) 3.82
Translocation of an immunoglobulin kappa locus to a region 3' of an unrearranged c-myc oncogene enhances c-myc transcription. Proc Natl Acad Sci U S A (1983) 3.75
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science (1984) 3.64
Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt. Proc Natl Acad Sci U S A (1983) 3.53
Transcriptional activation of the translocated c-myc oncogene in burkitt lymphoma. Proc Natl Acad Sci U S A (1983) 3.46
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J (1997) 3.34
Ethylene glycol poisoning: toxicokinetic and analytical factors affecting laboratory diagnosis. Clin Chem (1998) 3.32
Translocation of immunoglobulin VH genes in Burkitt lymphoma. Proc Natl Acad Sci U S A (1982) 3.30
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci U S A (1986) 3.19
Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature (1985) 2.91
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res (2001) 2.85
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Mechanisms of tumor progression. Cancer Res (1986) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci U S A (1989) 2.45
Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science (1987) 2.36
Mouse egg integrin alpha 6 beta 1 functions as a sperm receptor. Cell (1995) 2.32
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest (1983) 2.32
Mycosis fungoides palmaris et plantaris. Arch Dermatol (1995) 2.25
Herpesvirus infections in the acquired immune deficiency syndrome. JAMA (1984) 2.25
Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J Med (1999) 2.20
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci U S A (1993) 2.12
Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia. Proc Natl Acad Sci U S A (1989) 2.11
Isolated granulomas in Hodgkin's disease. N Engl J Med (1970) 2.10
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene (2007) 2.07
Violent injuries among women in an urban area. N Engl J Med (1999) 2.04
Quantitative studies on the mixed lymphocyte interaction in rats. V. Tempo and specificity of the proliferative response and the number of reactive cells from immunized donors. J Exp Med (1971) 2.04
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol (1996) 2.03
Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med (1984) 2.01
Cutaneous T-cell lymphoma in association with silicone breast implants. J Am Acad Dermatol (1995) 1.96
Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms. J Clin Invest (1988) 1.93
Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res (1993) 1.89
Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology (2010) 1.89
Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res (1991) 1.88
Neonatal cerebellar medulloblastoma originating from the fetal external granular layer. J Neuropathol Exp Neurol (1970) 1.88
cag+ Helicobacter pylori induce transactivation of the epidermal growth factor receptor in AGS gastric epithelial cells. J Biol Chem (2001) 1.87
Quantitative studies on the mixed lymphocyte interaction in rats. IV. Immunologic potentiality of the responding cells. J Exp Med (1970) 1.86
Evidence for the existence of multipotential lympho-hematopoietic stem cells in adult rat. J Cell Physiol (1970) 1.86
Molecular basis of human B cell neoplasia. Blood (1985) 1.85
Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med (1985) 1.83
Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res (2000) 1.80
A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A (1984) 1.79
Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene (2006) 1.77
Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science (1986) 1.75
Clinicopathologic studies of 117 untreated patients subjected to laparotomy for the staging of Hodgkin's disease. Cancer (1971) 1.74
Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol (1987) 1.74
Treatment of intraocular inflammatory disease with cyclosporin A. Lancet (1983) 1.74
Locus of the alpha-chain of the T-cell receptor is split by chromosome translocation in T-cell leukemias. Science (1985) 1.71
The alpha 6 beta 4 integrin and epithelial cell migration. Curr Opin Cell Biol (2001) 1.71
Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol (2001) 1.70
Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood (1991) 1.69
HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. J Immunol (1981) 1.69
Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A (1992) 1.65
Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology (2010) 1.63
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med (1999) 1.61
Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med (1992) 1.61
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res (2001) 1.60
Epidemiology of lymphomatoid papulosis. Cancer (1992) 1.60
Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature (1988) 1.60
Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Am J Surg Pathol (1998) 1.59
Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol (1998) 1.57
A human c-erbA oncogene homologue is closely proximal to the chromosome 17 breakpoint in acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1984) 1.55
The underreporting of cocaine-related trauma: drug abuse warning network reports vs hospital toxicology tests. Am J Public Health (1993) 1.52
A phorbol ester (TPA) can replace macrophages in human lymphocyte cultures stimulated with a mitogen but not with an antigen. J Immunol (1982) 1.52
Possible origin of the Reed-Sternberg cell from an interdigitating reticulum cell. Cancer Treat Rep (1982) 1.51
Exogenous immunoglobulin and the macrophage origin of Reed-Sternberg cells in Hodgkin's disease. N Engl J Med (1978) 1.51
Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells. J Cell Biol (1998) 1.50
Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N Engl J Med (1981) 1.48
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A (1998) 1.48
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells. Proc Natl Acad Sci U S A (1983) 1.48
The major non-integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2). J Biol Chem (1990) 1.47
The pathology of large granular lymphocyte leukemia. Hum Pathol (1989) 1.44
Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT. Bone Marrow Transplant (2010) 1.44
IL-12 synthesis by human Langerhans cells. J Immunol (1996) 1.43
Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia. Proc Natl Acad Sci U S A (1986) 1.41
Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest (1997) 1.41
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia (2001) 1.40
Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression. J Immunol (1986) 1.40
Danazol treatment of myelodysplastic syndromes. Br J Haematol (1991) 1.39
Expression of Hodgkin's disease associated antigen BLA.36 in anaplastic large cell lymphomas and lymphomatoid papulosis primarily of T-cell origin. Am J Clin Pathol (1995) 1.39
Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. Ther Drug Monit (1992) 1.39
γδ T-cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous γδ T-cell lymphomas. Br J Dermatol (2014) 1.38
Suppression of interleukin 2 receptor acquisition by monoclonal antibodies recognizing the 50 KD protein associated with the sheep erythrocyte receptor on human T lymphocytes. J Immunol (1985) 1.38